百奥泰维拉西塔单抗注射液上市许可申请获受理

Core Viewpoint - The company Baiotai has received approval from the National Medical Products Administration for the marketing authorization application of its investigational drug, BAT5906, which is indicated for neovascular (wet) age-related macular degeneration (nAMD) [1] Group 1 - BAT5906 is a recombinant humanized monoclonal antibody innovative drug developed and produced by the company [1] - The drug is an IgG1 type full-length antibody with a molecular weight of 149KDa [1] - BAT5906 specifically binds to human VEGF-A165 to inhibit neovascularization [1]